3B BlackBio Dx Reports H1'27 Performance and Growth Strategy
3B BlackBio Dx Ltd · Investor Presentation · 13 Nov 2026, 9:45 pm
3B BlackBio Dx Reports H1'27 Performance and Growth Strategy In H1'27, 3B BlackBio Dx posted consolidated revenue of ₹8,177.10 lakh, up 45.7% YoY, with PAT at ₹2,700.17 lakh and EPS of ₹31.51. Excluding Coris, revenue reached ₹6,413.72 lakh and PAT climbed 16.4% YoY to ₹3,269.49 lakh. The company holds a ~15% share in India's ₹500–600 Cr molecular diagnostics market and targets 15–20% growth in FY'27. Coris reduced H1 EBITDA losses by 45% and secured a €1.41M HAT order for delivery in Dec'26, while 3B pursues targeted M&A opportunities in the US.
Original exchange filing (PDF)
More announcements from 3B BlackBio Dx Ltd
- Analyst/Investor Meet intimation · 16 Nov 2026
- Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- Financial Results for the quarter and half-year ended 30th September, 2026 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- 3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Unaudited Standalone and .... · 13 Nov 2026
- Re-appointment of director who retires by rotation and being eligible, offers for re-appointment · 30 Sept 2026
- Scrutinizer''s Report and Voting report for 54th AGM · 30 Sept 2026
